Coronary events are currently the leading cause of death among men and women. In fact, these are often the most common deaths of people in the United States. While most often coronary conditions are treated through lifestyle changes such as ceasing smoking, losing weight, lowering blood pressure, medications or surgeries, other treatments such as oral chelation therapy are on the rise.
The compound used in this therapy has not been reviewed or rated by the U. S. Food and Drug Administration. Regardless, there were over 110,000 Americans whom had previously opted for the treatment prior to a 2007 study. Ultimately, the therapy promotes a chemical process which works to bind molecules to metals and minerals.
The therapy, originally used to eliminate excess and toxic metals and waste from the body is nothing new. For, EDTA has also been used in some Western medical practices with regards to lead poisoning and reducing iron overloads. However, when used to treat heart conditions, a health care provider must carefully inject a solution which includes disodium EDTA, an amino acid which is man made into the veins. Most often, individuals must receive more than thirty of these injections on a weekly basis until the treatment moves to a maintenance phase.
To decipher whether or not this therapy may be effective, the National Center for Complementary and Integrative Health or NCCIH in conjunction with the National Heart, Lung and Blood Institute sponsored a trial with regards to the benefits of these infusions in individuals with a negative cardiovascular medical history. Ultimately, the trial proved that the infusions did in fact provide the most reduction in cardiovascular events, though only in individuals whom also had diabetes.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
Sixteen percent of individuals receiving chelation therapy and fifteen percent provided placebos during the trial halted the injections due to complications. The results included four major events, including two deaths, one death in the placebo group and one in the chelation group. To date, the most prominent side effect appears to be a burning sensation at the injection site during the infusion.
As with almost all medical studies, more research is needed before a final determination as to the success of the therapy can be made. For, these reports are from the first study ever conducted. As such, the information provided through the study does not provide enough detail to support the infusions as being a safe or effective treatment for heart attack victims.
The compound used in this therapy has not been reviewed or rated by the U. S. Food and Drug Administration. Regardless, there were over 110,000 Americans whom had previously opted for the treatment prior to a 2007 study. Ultimately, the therapy promotes a chemical process which works to bind molecules to metals and minerals.
The therapy, originally used to eliminate excess and toxic metals and waste from the body is nothing new. For, EDTA has also been used in some Western medical practices with regards to lead poisoning and reducing iron overloads. However, when used to treat heart conditions, a health care provider must carefully inject a solution which includes disodium EDTA, an amino acid which is man made into the veins. Most often, individuals must receive more than thirty of these injections on a weekly basis until the treatment moves to a maintenance phase.
To decipher whether or not this therapy may be effective, the National Center for Complementary and Integrative Health or NCCIH in conjunction with the National Heart, Lung and Blood Institute sponsored a trial with regards to the benefits of these infusions in individuals with a negative cardiovascular medical history. Ultimately, the trial proved that the infusions did in fact provide the most reduction in cardiovascular events, though only in individuals whom also had diabetes.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
Sixteen percent of individuals receiving chelation therapy and fifteen percent provided placebos during the trial halted the injections due to complications. The results included four major events, including two deaths, one death in the placebo group and one in the chelation group. To date, the most prominent side effect appears to be a burning sensation at the injection site during the infusion.
As with almost all medical studies, more research is needed before a final determination as to the success of the therapy can be made. For, these reports are from the first study ever conducted. As such, the information provided through the study does not provide enough detail to support the infusions as being a safe or effective treatment for heart attack victims.
About the Author:
When you are looking for information about oral chelation, come to our web pages today. More details are available at http://www.heartdrop.com now.
0 comments:
Post a Comment